Compare Abeona Therapeutics Inc (ABEO) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Vanguard Short Term Corporate Bond ETF trades at $78.52. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | VCSH | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Fixed Income |
52-Week High | $7.45 | $80.20 |
52-Week Low | $4.17 | $78.41 |
Enterprise Value | $276.10M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
